Koyfin Home > Directory > Health Care > Revance Therapeutics > Gross Profit

Revance Therapeutics Gross Profit Chart (RVNC)

Revance Therapeutics annual/quarterly Gross Profit from 2012 to 2020. Gross profit is the profit after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Gross profit = Revenue - Cost of Goods Sold.
  • Revance Therapeutics Gross Profit for the quarter ending June 06, 2020 was $0m a 83.45% increase of 0m year over year
  • Revance Therapeutics Gross Profit for the last 12 months ending June 06, 2020 was $0m a -72.19% decrease of 0m year over year
  • Revance Therapeutics Annual Gross Profit for 2019 was $0m a -802.91% decrease of -3m from 2018
  • Revance Therapeutics Annual Gross Profit for 2018 was $4m a 92.97% increase of 3m from 2017
  • Revance Therapeutics Annual Gross Profit for 2017 was $0m a -14.50% decrease of 0m from 2016
Other Income Statement Metrics:
  • Revance Therapeutics EBITDA for the quarter ending December 12, 2018 was $-38m a 7.02% decrease of -3m year over year
  • Revance Therapeutics Net Income for the quarter ending September 09, 2018 was $-33m a -9.36% increase of 3m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Gross Profit Data

06/2020$0m
03/2020$0m
12/2019$0m
09/2019$0m
03/2019$0m
12/2018$0m
09/2018$2m
06/2018$1m
03/2018$0m
12/2017$0m

Annual RVNC Gross Profit Data

2019$0m
2018$4m
2017$0m
2016$0m
2015$0m
2014$0m
2013$1m
2012$1m
2011$1m